Table 2. Characteristics of children enrolled in the trial of quarterly albendazole versus placebo from age 15 months to five years, at the time of randomisation.
| Albendazole placebo | Albendazole | ||
| Number of children randomiseda | 1006 | 1010 | |
| Age at randomisation in years, mean ± SD | 1.52±0.54 | 1.52±0.50 | |
| Male | 531 (53%) | 510 (51%) | |
| Birthweight (362 mvb), mean ± SD | 3.19±0.48 | 3.16±0.50 | |
| HIV status | |||
| Unexposed | 894 (89%) | 914 (90%) | |
| Exposed, uninfected | 88 (9%) | 79 (8%) | |
| Exposed, infected | 18 (2%) | 13 (1%) | |
| Exposed, unknown | 6 (0.6%) | 4 (0.4%) | |
| P.falciparum at first annual visit (394 mv) | 41 (5%) | 51 (6%) | |
| Any worm infection at first annual visit (536 mv) | 19 (3%) | 22 (3%) | |
| Received deworming elsewhere during infancy (356 mv) | 132 (16%) | 161 (20%) | |
| Number of clinic visits for illness before randomisation, mean ± SD | 6.59±3.51 | 6.52±3.44 | |
| Any clinic visit pre-randomisation for: | |||
| Malaria | 361 (36%) | 337 (33%) | |
| Diarrhoea | 747 (74%) | 765 (76%) | |
| Pneumonia | 193 (19%) | 184 (18%) | |
| ‵ | Eczema | 68 (7%) | 98 (10%) |
a
The number of mothers with children randomised is lower than the number of children randomised due to 20 sets of twins;
b
mv: missing values;